1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic

Trial Profile

1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs INGN 225 (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 Dec 2014 to 1 Apr 2019.
    • 24 Oct 2017 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2018.
    • 15 May 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top